Flow surgery, focusing radiotherapy around the tumour site produces alike resemble results as treating the whole breast and had fewer long term side in truths, the authors said.
Radiotherapy is a standard treatment used after an efficacious to remove a tumour from a breast, even those deemed to be undergoing a low risk of their cancer returning.
The Cancer Research UK-funded clinical effort examined more than 2,000 women aged 50 or older who had anciently breast cancer with a low risk of returning.
The study, presented at the European Soul Cancer Conference in Amsterdam, saw the women split into three gangs following breast conserving surgery: one had full dose radiotherapy to the aggregate breast – the current standard treatment, the second group had the full quantity of radiotherapy to the area the tumour had been in – with a lower dose to take a rest of the whole breast, and the third group received the full dose to the quarter where the tumour had been, and were given no radiotherapy to the rest of the boob.
Five years after their treatment, only 1% or baby of women in each group had a recurrence of their cancer in their boob, according to the researchers, led by The Institute of Cancer Research, London.
Dr Charlotte Coles, clinical in in the arse lead and consultant clinical oncologist at Cambridge University Hospital NHS Instituting Trust, said: “We’re really pleased we have demonstrated a precise effective radiotherapy approach that also reduces the side causes of treatment.
“Minimising these long term side effects is main, as not only do they im ct on physical health, but they can also movement psychological distress.”
Professor Arnie Purushotham, senior clinical counsellor at Cancer Research UK, added: “This could result in a major change to how we treat breast cancer.
“If this changes practice it could obstruct many women having lasting effects from their treatment and bring down the discomfort and emotional stress women have from these side impressions.”
Charity Breast Cancer Now said that radiotherapy of the whole chest can cause changes in the appearance of the breast, resulting in psychological distress.
It also phrased that reduce toxicity from such treatment would be “of inestimable” to women.
Commenting on the study, Sally Greenbrook, policy manager at Titty Cancer Now, said: “These are early but promising results that could be of l ble benefit to breast cancer tients in the future.
“Radiotherapy is a standard segment of treatment for almost all women with breast cancer, and an opportunity to crop toxicity from treatment would be invaluable.
“The fact that this entry could also reduce the im ct of treatment on the appearance of their busts is also significant, rticularly at an already distressing time for tients.
“Bust cancer can of course recur many years after first diagnosis and so we now look forward to the planned backup of this study to confirm these results.”